Antibody-based therapies in multiple myeloma
Yu-Tzu Tai1, Kenneth C Anderson
1Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
Bone Marrow Research
|November 3, 2011
Summary
Monoclonal antibodies (mAbs) offer targeted therapy for multiple myeloma (MM) by engaging the immune system. Advances in antibody engineering have overcome immunogenicity, leading to FDA-approved treatments for cancer.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Multiple myeloma (MM) therapy requires improved treatment options.
- Monoclonal antibodies (mAbs) are being developed to target MM cells and the bone marrow microenvironment.
- Therapeutic mAbs offer specific tumor targeting and immune-mediated tumor cell lysis, distinct from small-molecule inhibitors.
Purpose of the Study:
- To review the advancements in monoclonal antibody (mAb) engineering for cancer therapy.
- To highlight the advantages of therapeutic mAbs over small-molecule inhibitors.
- To discuss the overcoming of immunogenicity as a critical hurdle in mAb development.
Main Methods:
- Review of antibody engineering technologies, including genetic recombination for humanization of rodent mAbs.
- Analysis of improved mAb characteristics: higher affinities, efficient selection, reduced immunogenicity, and enhanced effector functions.
- Examination of the impact of these advancements on the development and FDA approval of therapeutic antibodies.
Main Results:
- Antibody engineering has enabled large-scale production of therapeutic mAbs.
- Humanization techniques have significantly decreased antibody immunogenicity.
- Improved mAb affinities and effector functions enhance anti-cancer activity.
- These advancements have led to the successful FDA approval of therapeutic antibodies for various diseases.
Conclusions:
- Advancements in antibody engineering have largely overcome the challenge of immunogenicity in therapeutic mAbs.
- Monoclonal antibodies represent a promising class of drugs for multiple myeloma and other cancers.
- Further development of antibody engineering technologies will continue to drive innovation in cancer treatment.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:36Humoral Immune Responses
Overview